P. Desai

Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study)

K. P. Singh, H. Rao, N. Sengupta, 2020, Cardiovascular Diabetology.

Pde-5 inhibitors: are they enough for erectile dysfunction?

P. Desai, 2020 .

INFLUENCE OF ANTICONVULSANT THERAPY ON DOXACURIUM & PANCURONIUM-INDUCED PARALYSIS

P. Desai, Jones, Hewitt, 1989 .

Risk factors for multi-joint disease in patients with glucocorticoid-induced osteonecrosis

E. Stein, D. McMahon, G. Roboz, 2021, Osteoporosis International.